Aromatase deficiency in men: a clinical perspective

Area of Science:

• Endocrinology
• Genetics

Background:

• Human aromatase deficiency is a rare genetic syndrome resulting from loss-of-function mutations in CYP19A1, leading to congenital estrogen deprivation.
• This condition presents with distinct clinical features in affected males, including tall stature and skeletal abnormalities.

Purpose of the Study:

• To review the clinical presentation, diagnostic approaches, and treatment strategies for aromatase deficiency in men.
• To provide guidance for effective clinical management and lifelong hormone replacement therapy.

Main Methods:

• Review of clinical manifestations at presentation, including skeletal features and hormonal profiles.
• Diagnostic criteria involving unfused epiphyses, undetectable estradiol, and genetic confirmation of CYP19A1 mutations.
• Evaluation of transdermal estradiol therapy and monitoring parameters.

Main Results:

• Men with aromatase deficiency exhibit tall stature, delayed bone maturation, osteopenia/osteoporosis, and eunuchoid proportions.
• Diagnosis is supported by imaging (unfused epiphyses) and biochemical tests (undetectable estradiol), confirmed by CYP19A1 sequencing.
• Transdermal estradiol (approx. 25 microg/day) may suffice for lifelong replacement, with careful monitoring of BMD and hormone levels.

Conclusions:

• Early diagnosis of aromatase deficiency is vital to initiate estrogen therapy promptly after puberty.
• Estrogen replacement therapy helps prevent or mitigate skeletal complications associated with congenital estrogen deprivation.
• Monitoring bone mineral density and serum hormone levels (estradiol, LH, testosterone) are key indicators of successful treatment.